Bosutinib and Trametinib Inhibited Cell Growth on NSCLC and Erlotinib-Resistant NSCLC by Synergistically Targeting the EGFR Signaling Pathway. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.